Brief: Panbela Therapeutics Enters Into Sales Agreement With Roth Capital Partners
20/07/2022 12:02
July 20 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA THERAPEUTICS INC - ON JULY 19, 2022, PANBELA
THERAPEUTICS, INC. ENTERED INTO A SALES AGREEMENT WITH ROTH
CAPITAL PARTNERS, LLC
* PANBELA THERAPEUTICS- AGREEMENT TO SELL SHARES OF CO'S
COMMON
STOCK HAVING GROSS SALES PRICE OF UP TO $8.4 MILLION FROM TIME
TO TIME
* PANBELA THERAPEUTICS- INTENDS TO USE NET PROCEEDS FROM ATM
PROGRAM FOR CONTINUED CLINICAL DEVELOPMENT OF SBP-101 AND
EFLORNITHINE
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants